Abivax SA
PAR:ABVX

Watchlist Manager
Abivax SA Logo
Abivax SA
PAR:ABVX
Watchlist
Price: 115 EUR -4.49% Market Closed
Market Cap: 9B EUR

Abivax SA
Investor Relations

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Marc M. P. de Garidel M.B.A.
CEO & Director
No Bio Available
Dr. Philippe Pouletty M.D., Ph.D.
Founder & Director
No Bio Available
Mr. Didier Blondel
EVP, CFO & Board Secretary
No Bio Available
Mr. Didier Scherrer Ph.D.
Chief Scientific Officer
No Bio Available
Mr. Patrick Malloy
Senior Vice President of Investor Relations
No Bio Available
Ms. Ida Hatoum
Chief People & Compliance Officer
No Bio Available
Mr. Pierre Courteille M.B.A.
Chief Business Officer
No Bio Available
Mr. Jerome Denis Ph.D.
Executive Vice President of Process Development & Manufacturing
No Bio Available
Ms. Ana Sharma M.P.H.
VP & Global Head of Quality
No Bio Available
Hema Keshava
Senior Vice President of Finance
No Bio Available

Contacts

Address
ILE-DE-FRANCE
Paris
5, rue de la Baume
Contacts
+33153830841.0
www.abivax.com